Goodwin (JD Supra Denmark)

Researchers in Denmark recently published a report from an observational study of 802 Danish patients who switched from Remicade to the biosimilar infliximab product Remsima for the treatment of rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. In May 2015, Denmark implemented a national guideline mandating non-medical switching of all patients treated with Remicade to...